Press Release – New York, NY – October 21, 2025 – Sichenzia Ross Ference Carmel LLP announced that it represented D. Boral Capital LLC as the sole placement agent for the recently priced $1.1 million registered direct offering of XORTX Therapeutics Inc. (Nasdaq: XRTX), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease.
The D. Boral Capital team was led by David Boral, Philip Wiederlight, David Sans and Zach Perotto.
The SRFC team was led by partners Ross Carmel and Thiago Spercel, with associate Benjamin Sklar.